Marinus Pharmaceuticals Releases Key Findings from IV Ganaxolone Phase 3 RAISE Trial for Refractory Status Epilepticus

Marinus Pharmaceuticals, a company focused on developing innovative therapeutics for seizure disorders, has announced topline results from the Phase 3 RAISE trial (NCT04391569). This double-blind, randomized, placebo-controlled study assessed the…

Read MoreMarinus Pharmaceuticals Releases Key Findings from IV Ganaxolone Phase 3 RAISE Trial for Refractory Status Epilepticus

Takeda Reports Phase 3 Findings of Soticlestat (TAK-935) in Patients with Dravet Syndrome and Lennox-Gastaut Syndrome

Takeda Releases Phase 3 Topline Results for Soticlestat (TAK-935) in Dravet Syndrome and Lennox-Gastaut Syndrome OSAKA, Japan & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Takeda (TSE:4502/NYSE The SKYLINE trial (TAK-935-3001) was a multicenter, randomized,…

Read MoreTakeda Reports Phase 3 Findings of Soticlestat (TAK-935) in Patients with Dravet Syndrome and Lennox-Gastaut Syndrome

Celltrion Unveils Promising Phase III Results for CT-P47, a Biosimilar to RoActemra®, in RA Patients at EULAR 2024

Celltrion today presented positive Phase III data for CT-P47, a biosimilar referencing RoActemra® in patients with moderate-to-severe rheumatoid arthritis (RA), at the Annual European Congress of Rheumatology (EULAR) 2024. The…

Read MoreCelltrion Unveils Promising Phase III Results for CT-P47, a Biosimilar to RoActemra®, in RA Patients at EULAR 2024

Genentech’s Phase III STARGLO Study: Columvi Extends Survival in Relapsed/Refractory Diffuse Large B-cell Lymphoma

Genentech, part of the Roche Group, announced significant results from its Phase III STARGLO study of Columvi® (glofitamab-gxbm) with gemcitabine and oxaliplatin (GemOx) versus Rituxan® (rituximab) with GemOx (R-GemOx) in…

Read MoreGenentech’s Phase III STARGLO Study: Columvi Extends Survival in Relapsed/Refractory Diffuse Large B-cell Lymphoma